Cerebral Microbleeds as a Biomarker in Alzheimer’S Disease? A Review in The Field

Abstract

Cerebral microbleeds (CMBs) are a marker of small vessel disease, increasingly recognized as being of importance in the Alzheimer’s disease (AD) process. CMBs influence in AD, and its longitudinal impact on disease progression is however still unknown. CMBs show several associations with AD across studies, are associated with decreased cerebrospinal fluid amyloid levels and are related with the ApoE ∊4 allele, as well as other imaging manifestations typical for small vessel disease. CMBs, in addition to other markers of small vessel disease, are important to discover further in order to discern possible AD phenotypes.

Keywords::

• Alzheimer’s disease
• amyloid
• apolipoprotein ∊ allele
• biomarkers
• cerebral microbleeds
• cerebrospinal fluid
• MRI
• small vessel disease

Financial & competing interests disclosure

The authors are funded by The Swedish Dementia Association and Stockholm County Council. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

The authors are funded by The Swedish Dementia Association and Stockholm County Council. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.